Galectin Therapeutics (GALT) CMO receives 65K options and 100K RSUs

Rhea-AI Filing Summary

Galectin Therapeutics reported new equity awards to its Chief Medical Officer, Jamil Khurram. On January 16, 2026, Khurram received stock options covering 65,000 shares of common stock with an exercise price of $3.04 per share, expiring on January 16, 2036. These options vest in four equal 25% installments on June 30, 2026, December 31, 2026, June 30, 2027 and December 31, 2027.

On the same date, Khurram was also granted 100,000 Restricted Stock Units under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. These RSUs vest 100% on the earlier of December 31, 2026 or the signing of a partnership agreement, and, if vested, convert into common stock on a one-for-one basis. Both awards are reported as directly owned.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jamil Khurram

(Last) (First) (Middle)

4960 PEACHTREE INDUSTRIAL BLVD

SUITE 240

(Street)

NORCROSS GA 30071

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GALECTIN THERAPEUTICS INC [ GALT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/16/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)(1)	$3.04	01/16/2026		A		65,000		(2)	01/16/2036	Common Stock	65,000	$0	65,000	D
Restricted Stock Unit(1)	(4)	01/16/2026		A		100,000		(3)	(3)	Common Stock	100,000	$0	100,000	D

Explanation of Responses:

1. Issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.

2. The options vest as follows: 25% on each of June 30, 2026? December 31, 2026? June 30, 2027? and December 31, 2027.

3. Restricted Stock Units vest 100% on the earlier of December 31, 2026 or signing of a partnership agreement.

4. The Restricted Stock Units, if vested, convert into Common Stock on a one for one basis.

	Jack W. Callicutt	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did GALT report for Jamil Khurram?

Galectin Therapeutics reported that Chief Medical Officer Jamil Khurram received 65,000 stock options and 100,000 Restricted Stock Units on January 16, 2026, both as new awards.

What are the key terms of the 65,000 Galectin Therapeutics (GALT) stock options?

The 65,000 stock options have an exercise price of $3.04 per share and expire on January 16, 2036. They vest 25% on each of June 30, 2026, December 31, 2026, June 30, 2027 and December 31, 2027.

How do the 100,000 Galectin Therapeutics (GALT) RSUs granted to the CMO vest?

The 100,000 Restricted Stock Units vest 100% on the earlier of December 31, 2026 or the signing of a partnership agreement. If vested, they convert into common stock on a one-for-one basis.

Are the new Galectin Therapeutics (GALT) equity awards held directly by the CMO?

Yes. The Form 4 shows both the 65,000 stock options and 100,000 RSUs as directly owned by Chief Medical Officer Jamil Khurram.

Under which plan were the new GALT stock options and RSUs issued?

Both the stock options and Restricted Stock Units were issued under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan, as noted in the footnotes.

What does the partnership agreement condition mean for GALT RSU vesting?

The 100,000 RSUs vest either on December 31, 2026 or when a partnership agreement is signed, whichever occurs first. That event would fix the vesting date.